

Limited Submission Funding Opportunities – updated 5/21/21

Please be aware that any grant that brings in less than 15% in indirect costs (IDC) will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

For MGH investigators selected through a competitive process as the institutional nominee for any limited submission funding opportunities, in situations in which the grant will bring in less than 15% indirect cost (IDC), ECOR will cover the IDC gap up to a maximum of \$50,000 per year. In order to optimize the distribution of limited ECOR funds across the MGH research community, it is expected that PIs and departments will work together to cover the remaining IDC shortfall.

This policy is only effective for those limited submission opportunities in which MGH is invited to submit its own nominee(s). This policy does not apply for those limited submission opportunities in which the MGH investigator must apply through HMS.

For further questions, please contact ECOR at ecor@mgh.harvard.edu

We ask that all MGH Investigators interested in applying for any limited submission award submit a Letter of Intent (see detailed instructions below) to the MGH Executive Committee on Research (ECOR) by the deadline indicated for each award to be considered to receive an institutional nomination.

Process

Submit a one- to two-page Letter of Intent (LOI) to the MGH Executive Committee on Research (ECOR) via email to ecor@mgh.harvard.edu. In addition to your LOI, please include an NIH Biosketch.

The letter of intent should include:

1. Name of the Principal Investigator with appropriate contact information
2. A descriptive title of the potential application
3. Brief description of the project
4. Brief description of why you specifically should be selected to receive institutional nomination for this award

In the event that there is more than one MGH investigator interested in applying for a limited submission award, the LOIs will be used to assess candidates and a review and selection process will take place.

If there is a limited submission funding opportunity you do not see listed below or you have any additional questions, please let us know at ecor@mgh.harvard.edu.

CURRENT OPPORTUNITIES

1. 1907 Trailblazer Award

<https://www.1907-research.org/apply>

MGH LOI Deadline: 5/21/21

Sponsor Application Deadline: 6/30/21

The 1907 Trailblazer Award was established to encourage high-impact, step-change approaches to research in the brain and mind sciences for mental health. In addition to supporting a specific research project, the Award intends to increase the size of the talent pool of early career investigators researching causes & cures for mental illness. The sponsor promotes these aims by providing a US \$100,000 research grant on an unrestricted basis, a US \$20,000 prize to enhance the economic security of the scientist, and travel & expense coverage for attendance at two annual meetings. Each winner will

Limited Submission Funding Opportunities – updated 5/21/21

be invited to present interim findings (year 1) and final findings (year 2), where they can form scientific relationships with other Fellows, our Advisory Board and our Research Committee. They aim to build community and provide value to the scientist in excess of the monetary element.

Projects must be grounded in the study of biological mechanisms underlying brain function, cognitive processes, and/or consciousness. We support projects for basic science in addition to near-term applications (e.g. disruptive technologies and potential clinical interventions).

- Applicants must be within ten years of the date when PhD/MD degree was awarded (whichever came later and with exceptions for maternity leave, paternity leave and other excused absences) For clinical scientists, the 10- year clock starts upon completion of all residency and fellowships. Please use April 16, 2021 as the end date for calculation of the 10-year period.
- Applicants will currently be employed by a university or public research institute in the US, the UK, or Canada, with full-time employment guaranteed for the duration of the project. [1] [SEP]
- Applicants will have demonstrated independence from senior colleagues. They must be able to initiate and direct their own research as principal investigator, have full responsibility for running their labs and full control of their research funds.
- Applicants will have a strong track record of scientific publications relevant to their research program
- Research applications may be related to but cannot be identical to any other currently funded projects

In addition to the basic requirements for an ECOR letter of intent, please be sure to include the following information:

1. What is the novel idea and what is the potential impact of your idea to the field?
2. What tools, resources, and relationships do you have to enable you to complete the research?

This particular LOI may 2-3 pages long. Please be sure to include a biosketch as well.

2. Population Dynamics Centers Research Infrastructure Program FY 2022 (P2C Clinical Trial Not Allowed)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-22-013.html>

MGH LOI Deadline: 5/25/21

NIH LOI Deadline: 6/29/21

NIH Application Deadline: 7/29/21

The goal of this funding opportunity announcement (FOA) is to advance the field of population dynamics research by increasing research impact, innovation, and productivity; developing junior scientists; and maximizing the efficiency of research support.

Limited Submission Funding Opportunities – updated 5/21/21

3. Clinical and Translational Science Award (U54 Clinical Trial Optional) – NEW!

<https://grants.nih.gov/grants/guide/pa-files/PA-18-940.html>

MGH LOI Deadline: 5/31/21

NIH LOI Deadline: 6/15/21

NIH Application Deadline: 7/15/21

The purpose of this funding opportunity announcement (FOA) is to invite applications to participate in the Clinical and Translational Science Award (CTSA) Program which supports high quality translational science and clinical research locally, regionally and nationally and fosters innovation in research methods, training, and career development.

4. Limited Competition Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 – Clinical Trial Not Allowed)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-002.html>

MGH LOI Deadline: 6/09/21

NIH LOI Deadline: 7/09/21

NIH Application Deadline: 8/09/21

The purpose of this Funding Opportunity Announcement (FOA) is to support a coordinating center (CC), which will coordinate research efforts across the NIDA funded longitudinal cohorts that address emerging and high priority research on HIV/AIDS in the context of substance use and substance use disorders (SUD). The coordinating center will serve as 1) a national data and specimen resource that harmonizes and collects data and biological samples from the NIDA cohorts and affiliated studies, and enables additional research efforts through virtual repositories; 2) a facilitator of current and future research at the intersection of HIV and substance use and SUD; and 3) the central hub for organizing and enabling communication within and outside the NIDA cohort studies program, including annual meetings, advisory and scientific oversight committees.

5. Centers for HIV Structural Biology (U54 Clinical Trial Not Allowed)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-030.html>

MGH LOI Deadline: 8/16/21

NIH LOI Deadline: 9/13/21

NIH Application Deadline: 10/13/21

The purpose of this Funding Opportunity Announcement (FOA) is to support dynamic, multidisciplinary consortia of structural biologists, virologists, and computational scientists to resolve complex biological structures relevant to HIV prevention, treatment, and cure. The consortia are expected to leverage common resources, facilitate new collaborations, and engage and support the next generation of HIV structural biology researchers.